ibandronic acid has been researched along with Cholera Infantum in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Modi, A; Sajjan, S; Siris, ES; Steve Fan, CP | 1 |
| Blumentals, WA; Cole, RE; Harris, ST; Huang, L; Silverman, SL | 1 |
| Barrett, J; Bonvoisin, B; Dumont, E; Reginster, JY; Wilson, KM | 1 |
| Ettinger, MP; Felsenberg, D; Harris, ST; Hiltbrunner, V; Miller, PD; Schimmer, RC; Skag, A; Wasnich, R; Wilson, K | 1 |
| Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM | 1 |
| Civitelli, R; Emkey, R; Strampel, W | 1 |
| Babbitt, AM; Bone, HG; Lewiecki, EM; Ozturk, ZE; Piziak, VK | 1 |
2 review(s) available for ibandronic acid and Cholera Infantum
| Article | Year |
|---|---|
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Bone; Gastrointestinal Diseases; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Renal Insufficiency; Risedronic Acid | 2007 |
3 trial(s) available for ibandronic acid and Cholera Infantum
| Article | Year |
|---|---|
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Area Under Curve; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Feasibility Studies; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides | 2005 |
Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Upper Gastrointestinal Tract | 2005 |
Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Follow-Up Studies; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis; Prospective Studies; Time Factors; Treatment Outcome | 2008 |
2 other study(ies) available for ibandronic acid and Cholera Infantum
| Article | Year |
|---|---|
Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis.
Topics: Administrative Claims, Healthcare; Aged; Alendronate; Databases, Factual; Diphosphonates; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; United States | 2015 |
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Topics: Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Risk Factors | 2009 |